ANAPTYSBIO, INC. Available-for-sale Securities, Gross Realized Gain (Loss), Excluding Other than Temporary Impairments
ANAPTYSBIO, INC. (ANAB) reported Available-for-sale Securities, Gross Realized Gain (Loss), Excluding Other than Temporary Impairments of $83.00 thousand for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-08.
Discontinued › Income Statement › Other Income
us-gaap:AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments · last filed 2018-05-08
- ANAPTYSBIO, INC. available-for-sale securities, gross realized gain (loss), excluding other than temporary impairments for the quarter ending 2018-03-31 was $83.00K.
- ANAPTYSBIO, INC. available-for-sale securities, gross realized gain (loss), excluding other than temporary impairments for the quarter ending 2017-12-31 was $5.00K.
- ANAPTYSBIO, INC. available-for-sale securities, gross realized gain (loss), excluding other than temporary impairments for the quarter ending 2017-03-31 was $0.00.
- ANAPTYSBIO, INC. available-for-sale securities, gross realized gain (loss), excluding other than temporary impairments for the quarter ending 2016-12-31 was $0.00.
- ANAPTYSBIO, INC. available-for-sale securities, gross realized gain (loss), excluding other than temporary impairments for fiscal 2017 was -$11.00K.
- ANAPTYSBIO, INC. available-for-sale securities, gross realized gain (loss), excluding other than temporary impairments for fiscal 2016 was $0.00.
- ANAPTYSBIO, INC. available-for-sale securities, gross realized gain (loss), excluding other than temporary impairments for fiscal 2015 was $0.00.
| Period end | Available-for-sale Securities, Gross Realized Gain (Loss), Excluding Other than Temporary Impairments 3 month | Available-for-sale Securities, Gross Realized Gain (Loss), Excluding Other than Temporary Impairments 6 month | Available-for-sale Securities, Gross Realized Gain (Loss), Excluding Other than Temporary Impairments 9 month | Available-for-sale Securities, Gross Realized Gain (Loss), Excluding Other than Temporary Impairments 12 month |
|---|---|---|---|---|
| 2018-03-31 | $83.00K 10-Q · filed 2018-05-08 | $88.00K derived: sum of 2 quarters · filed 2018-05-08 | ||
| 2017-12-31 | $5.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-05 | -$11.00K 10-K · filed 2018-03-05 | ||
| 2017-09-30 | -$16.00K 10-Q · filed 2017-11-07 | |||
| 2017-03-31 | $0.00 10-Q · filed 2018-05-08 | $0.00 derived: sum of 2 quarters · filed 2018-05-08 | ||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-05 | $0.00 10-K · filed 2018-03-05 | ||
| 2016-09-30 | $0.00 10-Q · filed 2017-11-07 | |||
| 2015-12-31 | $0.00 10-K · filed 2018-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |